MnSOD Mimetic BMX-001

Phase 2Small molecule

MnSOD Mimetic BMX-001 is one of 2 small molecule programs targeting Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Recruiting

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Phase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 2

MnSOD Mimetic BMX-001

NNRG Oncology

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8

NCT06532279

Clinical

Trials by Indication[1]

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81 trial

A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation

Recruiting·NNRG Oncology·Phase 2·NCT06532279·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MnSOD Mimetic BMX-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MnSOD Mimetic BMX-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MnSOD Mimetic BMX-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NRG Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNRG Oncology

MnSOD Mimetic BMX-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81 trial

References

Drug Info

Quick Facts

Related News